New hope for tough lung cancer: expanded access to targeted drug
NCT ID NCT07535359
First seen May 05, 2026 · Last updated Jun 17, 2026 · Updated 7 times
Summary
This program provides early access to an experimental drug called ifinatamab deruxtecan (I-DXd) for people with extensive-stage small cell lung cancer who have already tried at least two prior treatments, including platinum-based chemotherapy. It is for patients who have no other suitable options and cannot join a clinical trial. The goal is to offer a potential treatment option while gathering more information about the drug's effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Central Care Cancer Center
AVAILABLESalina, Kansas, 67401, United States
Contact
-
Duke Cancer Institute
AVAILABLEDurham, North Carolina, 27710, United States
Contact
-
University of Texas Southwestern Medical
AVAILABLEDallas, Texas, 75390, United States
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.